Elcin Barker Ergun

From WikiProjectMed
Jump to navigation Jump to search

Elcin Barker Ergun is a business leader in the pharmaceutical industry.[1] In September 2019 she was appointed chief executive officer and member of the board of directors of the Italian company Menarini Group.[2][3][4]

Biography

Ergun graduated from TED Ankara College (high school) in Turkey, where she also played basketball and handball and was a member of the team that won the national championship three times. Elcin has a Bachelor of Science degree in computer engineering from Middle East Technical University in Ankara and an MBA from INSEAD (Institut Europeen d’Administration Des Affaires).[5]

Ergun's career started as a software engineer, working for five years in IT management in Amsterdam for ITT Corporation.[6] After her MBA in France, Ergun moved to the UK, leading marketing and supply chain projects at the Northern European head office of Honeywell[6] and later continued as subsidiary chief financial officer.[6] Ergun entered the pharmaceutical industry as chief financial officer of the Turkish subsidiary of GlaxoSmithKline.[7]

After joining Merck KGaA's Healthcare business,[2][5][7] Elcin took on roles of increasing seniority within the organisation becoming Executive Vice President and Head of Global Commercial for Merck Serono,[6] achieving significant leadership and business transformation across global commercial operations.[6] This followed her role as Senior Vice President and Head of Intercontinental Region, across the Middle East, Africa, and Russia/CIS countries.

Before she joined Menarini Group, Elcin was based in Boston[5][8] for three years as Executive Vice President,[5] Head of New Businesses[5][8] at Merck Healthcare.[9]

Under Ergun's leadership, Menarini has accomplished milestones such as the 2020 acquisition of Stemline Therapeutics,[10] a U.S. commercial-stage biopharmaceutical company,[11] formerly a public listed organization quoted on NASDAQ,[10] focused on the development and commercialization of novel oncology therapeutics.[10][11]

References

  1. ^ "Revitalizing Purpose: Q&A with Elcin Barker Ergun | Thought Leadership". Russell Reynolds Associates. Retrieved 2021-07-18.
  2. ^ a b "Menarini: Elcin Barker Ergun amministratore delegato Gruppo". 12 September 2019.
  3. ^ "Elcin Barker Ergun, A Menarini Indus Farmaceutiche: Profile and Biography". Bloomberg News.
  4. ^ "Menarini appoints new chief executive". thepharmaletter.com. Retrieved 2021-07-18.
  5. ^ a b c d e marchitto (2020-12-14). "Menarini: Elcin Barker Ergun Group CEO". Adnkronos. Retrieved 2021-04-22.
  6. ^ a b c d e "Keynote speaker - Elcin Ergun | HBA". hbanet.org. Retrieved 2021-04-22.
  7. ^ a b AG, BIOCOM. "Elcin Barker Ergun becomes Menarini CEO". european-biotechnology.com. Retrieved 2021-04-22.
  8. ^ a b Volonté, Chiara (2019-09-16). "Menarini: la via all'internazionalizzazione è donna". Industria Italiana (in Italian). Retrieved 2021-08-31.
  9. ^ "Vibrant Science & Technology - EMD Group". merckgroup.com. Retrieved 2021-08-31.
  10. ^ a b c "Menarini Group Completes Acquisition of Stemline Therapeutics - ANSA.it". ansa.it. Retrieved 2021-08-31.
  11. ^ a b "About Us". Stemline Therapeutics. Retrieved 2021-08-31.
Retrieved from "https://mdwiki.org/wiki/Elcin_Barker_Ergun"